Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | MDM4 | O15151 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29401786 | 1.00 | CASP3 (0.52) | CASP3KMT2APIN1EPHX2MDM4 | |
| SCHEMBL3070048 | 1.00 | CASP3 (0.52) | CASP3KMT2APIN1EPHX2MDM4 | |
| SCHEMBL30656017 | 1.00 | CASP3 (0.52) | CASP3KMT2APIN1EPHX2MDM4 | |
| SCHEMBL5706475 | 0.92 | CASP3 (0.47) | CASP3KMT2APIN1EPHX2MDM4 | |
| SCHEMBL29401235 | 0.90 | CASP3 (0.46) | CASP3KMT2APIN1EPHX2 | |
| SCHEMBL3060107 | 0.90 | CASP3 (0.46) | CASP3KMT2APIN1EPHX2 | |
| SCHEMBL29692811 | 0.89 | CTSB (0.48) | CASP3MDM4TP53MDM2 | |
| SCHEMBL7650015 | 0.88 | CASP3 (0.48) | CASP3KMT2APIN1EPHX2MDM4 | |
| SCHEMBL12798422 | 0.88 | CASP3 (0.48) | CASP3KMT2APIN1EPHX2MDM4 | |
| SCHEMBL29402434 | 0.88 | CASP3 (0.48) | CASP3KMT2APIN1EPHX2MDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250223302-A1 | CAMPTOTHECINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | R.P. SCHERER TECHNOLOGIES, LLC | 2025-07-10 | — | — | US | disclosed |
| CN-119896745-A | Glycoside-containing peptide linkers for antibody-drug conjugates | R.P.谢勒技术有限责任公司 | 2025-04-29 | — | — | CN | disclosed |
| CN-119896746-A | Glycoside-containing peptide linkers for antibody-drug conjugates | R.P.谢勒技术有限责任公司 | 2025-04-29 | — | — | CN | disclosed |
| CN-113874046-B | Glycoside-containing peptide linkers for antibody-drug conjugates | R.P.谢勒技术有限责任公司 | 2025-02-28 | — | — | CN | disclosed |
| US-12187745-B2 | Camptothecine antibody-drug conjugates and methods of use thereof | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2025-01-07 | — | — | US | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| US-20240197907-A1 | Dual-Cleavage Ester Linkers for Antibody-Drug Conjugates | ARES CAPITAL CORPORATION, AS COLLATERAL AGENT | 2024-06-20 | — | — | US | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| EP-4301415-A1 | BRANCHED LINKERS FOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | R.P. Scherer Technologies, LLC (US) | 2024-01-10 | — | — | EP | disclosed |
| CN-117279662-A | Branched linkers for antibody-drug conjugates and methods of use thereof | R.P.谢勒技术有限责任公司 | 2023-12-22 | — | — | CN | disclosed |
| US-20230277676-A1 | CAMPTOTHECINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | ARES CAPITAL CORPORATION, AS COLLATERAL AGENT | 2023-09-07 | — | — | US | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| US-11564989-B2 | Camptothecine antibody-drug conjugates and methods of use thereof | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2023-01-31 | — | — | US | disclosed |
| WO-2022187370-A1 | BRANCHED LINKERS FOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2022-09-09 | — | — | WO | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| US-20220241423-A1 | CAMPTOTHECINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | ARES CAPITAL CORPORATION, AS COLLATERAL AGENT | 2022-08-04 | — | — | US | disclosed |
| US-20220226490-A1 | Glycoside-Containing Peptide Linkers for Antibody-Drug Conjugates | ARES CAPITAL CORPORATION, AS COLLATERAL AGENT | 2022-07-21 | — | — | US | disclosed |
| WO-2022155362-A1 | DUAL-CLEAVAGE ESTER LINKERS FOR ANTIBODY-DRUG CONJUGATES | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2022-07-21 | — | — | WO | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| US-11236059-B2 | Targeted cytotoxic ratjadone derivatives and conjugates thereof | HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH (DE) | 2022-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240197907-A1 | Dual-Cleavage Ester Linkers for Antibody-Drug Conjugates | ADAM8, BCR, JMJD7 | CASP3 234/4885KMT2A 1281/4885PIN1 1761/4885 |
| US-20230277676-A1 | CAMPTOTHECINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | DCTD, ADCY8, ADCY3 | CASP3 1718/4885KMT2A 1187/4885PIN1 1747/4885 |
| US-12187745-B2 | Camptothecine antibody-drug conjugates and methods of use thereof | DCTD, ADCY8, ADCY3 | CASP3 1718/4885KMT2A 1187/4885PIN1 1747/4885 |
| US-20250223302-A1 | CAMPTOTHECINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | DCTD, ADCY8, ADCY3 | CASP3 1718/4885KMT2A 1187/4885PIN1 1747/4885 |
| US-20220241423-A1 | CAMPTOTHECINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | DCTD, ADCY8, ADCY3 | CASP3 1718/4885KMT2A 1187/4885PIN1 1747/4885 |
| US-11236059-B2 | Targeted cytotoxic ratjadone derivatives and conjugates thereof | PICALM, CD47, RABGGTB | CASP3 124/4885KMT2A 2867/4885PIN1 966/4885 |
| US-20220226490-A1 | Glycoside-Containing Peptide Linkers for Antibody-Drug Conjugates | DNPEP, VIP, SI | CASP3 694/4885KMT2A 1959/4885PIN1 660/4885 |
| US-11564989-B2 | Camptothecine antibody-drug conjugates and methods of use thereof | DCTD, ADCY8, ADCY3 | CASP3 1718/4885KMT2A 1187/4885PIN1 1747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.